Rob Zuiker

Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials

Lui Franciosi, Zuzana Diamant, Katharine H. Banner et al. · The Lancet Respiratory Medicine · 2013 · 165 citations

Medicine, Pharmacology, Pharmacotherapy +12

Setipiprant, a selective <scp>CRTH</scp>2 antagonist, reduces allergen‐induced airway responses in allergic asthmatics

Zuzana Diamant, Patricia N. Sidharta, Dave Singh et al. · Clinical & Experimental Allergy · 2014 · 83 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder

Kasper Recourt, Peter de Boer, Rob Zuiker et al. · Translational Psychiatry · 2019 · 83 citations · Full text

Medicine, Pharmacology, Psychiatry +17

The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia

Sander Brooks, Gabriël E. Jacobs, Peter de Boer et al. · Journal of Psychopharmacology · 2019 · 73 citations

Medicine, Pharmacology, Psychiatry +17

Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study

Randall L. Morrison, Maggie Fedgchin, Jaskaran Singh et al. · Psychopharmacology · 2018 · 72 citations · Full text

Medicine, Pharmacology, Psychology +15